Arcus data the latest twist in the TIGIT story

ARTICLE | Product Development

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence

November 5, 2024 11:50 PM UTC

The TIGIT rollercoaster takes another turn, with overall survival data from a small study of Arcus’ domvanalimab that could swing sentiment in a positive direction, if slightly.

Arcus Biosciences Inc. (NYSE:RCUS) reported, ahead of a presentation at the Society for Immunotherapy of Cancer (SITC) conference this week, that domvanalimab plus PD-1 inhibitor zimberelimab reduced the risk of death by 36% when used as first-line therapy in patients with PD-L1-high non-small cell lung cancer (NSCLC) over zimberelimab alone…